139 related articles for article (PubMed ID: 11586018)
1. Large B-cell lymphoma of the leg--complete remission with perilesional interferon alpha.
Wollina U; Mentzel T; Graefe T
Dermatology; 2001; 203(2):165-7. PubMed ID: 11586018
[TBL] [Abstract][Full Text] [Related]
2. Primary cutaneous marginal center lymphoma - complete remission induced by interferon alpha2a.
Wollina U; Hahnfeld S; Kosmehl H
J Cancer Res Clin Oncol; 1999; 125(5):305-8. PubMed ID: 10359136
[TBL] [Abstract][Full Text] [Related]
3. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
[TBL] [Abstract][Full Text] [Related]
4. Multilesional primary cutaneous diffuse large B-cell lymphoma responsive to antibiotic treatment.
Hofbauer GF; Kessler B; Kempf W; Nestle FO; Burg G; Dummer R
Dermatology; 2001; 203(2):168-70. PubMed ID: 11586019
[TBL] [Abstract][Full Text] [Related]
5. Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab).
Aboulafia DM
Am J Clin Oncol; 2001 Jun; 24(3):237-40. PubMed ID: 11404492
[TBL] [Abstract][Full Text] [Related]
6. Activity of interferon-alpha in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma.
Armitage JO; Coiffier B
Ann Oncol; 2000 Mar; 11(3):359-61. PubMed ID: 10811506
[No Abstract] [Full Text] [Related]
7. Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29 patients.
Bekkenk MW; Vermeer MH; Geerts ML; Noordijk EM; Heule F; van Voorst Vader PC; van Vloten WA; Meijer CJ; Willemze R
J Clin Oncol; 1999 Aug; 17(8):2471-8. PubMed ID: 10561311
[TBL] [Abstract][Full Text] [Related]
8. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
Bonnekoh B; Schulz M; Franke I; Gollnick H
J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303
[TBL] [Abstract][Full Text] [Related]
9. Complete response of a primary cutaneous T-cell-rich B cell lymphoma treated with interferon alpha2a.
Wollina U
J Cancer Res Clin Oncol; 1998; 124(2):127-9. PubMed ID: 9654196
[TBL] [Abstract][Full Text] [Related]
10. Primary cutaneous large B-cell lymphoma of scalp: Case report of a rare variant.
Khatib Y; Dande M; Patel RD; Makhija M
Indian J Pathol Microbiol; 2017; 60(2):268-271. PubMed ID: 28631652
[TBL] [Abstract][Full Text] [Related]
11. Primary cutaneous diffuse large B cell lymphoma: a clinically aggressive case.
Narimatsu H; Morishita Y; Shimada K; Ozeki K; Kohno A; Kato Y; Nagasaka T
Intern Med; 2003 Apr; 42(4):354-7. PubMed ID: 12729326
[TBL] [Abstract][Full Text] [Related]
12. [Management of cutaneous B-cell lymphoma: recommendations of the French cutaneous lymphoma study group].
Grange F; D'Incan M; Ortonne N; Dalac S; Laroche L; Beylot-Barry M; Delfau-Larue MH; Vergier B; Bagot M;
Ann Dermatol Venereol; 2010; 137(8-9):523-31. PubMed ID: 20804896
[TBL] [Abstract][Full Text] [Related]
13. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.
Heinzerling LM; Urbanek M; Funk JO; Peker S; Bleck O; Neuber K; Burg G; von Den Driesch P; Dummer R
Cancer; 2000 Oct; 89(8):1835-44. PubMed ID: 11042581
[TBL] [Abstract][Full Text] [Related]
14. Primary cutaneous B-cell lymphoma: treatment with low dose intralesional recombinant interferon-alpha 2A.
Rubegni P; De Aloe G; Pianigiani E; Lazzi S; Fimiani M
J Eur Acad Dermatol Venereol; 1999 Jan; 12(1):70-1. PubMed ID: 10188159
[No Abstract] [Full Text] [Related]
15. Complete remission of a primary cutaneous follicle-center cell lymphoma (EORTC criteria)/diffuse large B-cell lymphoma (WHO criteria) by single first-line therapy with rituximab.
Nagasaka A; Matsue H; Kawamura T; Kanzaki M; Inozume T; Nakamura Y; Shimzu A; Shibagaki N; Yanagi M; Shimada S
J Dermatol; 2006 May; 33(5):377-9. PubMed ID: 16700675
[No Abstract] [Full Text] [Related]
16. Central nervous system involvement from primary cutaneous large B-cell lymphoma of the leg.
Gimeno E; Gimenez MT; Alvarez-Larrán A; Gallardo F; Ferrer A; Bellosillo B; Besses C; Salar A
Leuk Res; 2009 Jul; 33(7):e59-60. PubMed ID: 19019429
[No Abstract] [Full Text] [Related]
17. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
18. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases.
Grange F; Beylot-Barry M; Courville P; Maubec E; Bagot M; Vergier B; Souteyrand P; Machet L; Dalac S; Esteve E; Templier I; Delaporte E; Avril MF; Robert C; Dalle S; Laroche L; Delaunay M; Joly P; Wechsler J; Petrella T
Arch Dermatol; 2007 Sep; 143(9):1144-50. PubMed ID: 17875875
[TBL] [Abstract][Full Text] [Related]
19. [Primary pulmonary lymphoma presenting as an endobronchial polypoid tumor].
Miyata Y; Okano R; Kuratomi Y
Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Aug; 35(8):910-4. PubMed ID: 9366169
[TBL] [Abstract][Full Text] [Related]
20. Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin's lymphoma.
Colovic N; Jurisic V; Terzic T; Atkinson HD; Colovic M
Arch Dermatol Res; 2009 Oct; 301(9):689-92. PubMed ID: 19495780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
